The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III, multicenter, double-blind, randomized trial of celecoxib versus placebo in primary breast cancer patients: Randomized European Celecoxib Trial (REACT).
R. C. Coombes
Research Funding - Pfizer
G. Von Minckwitz
Research Funding - Pfizer
J. Hicks
No relevant relationships to disclose
P. Klare
No relevant relationships to disclose
A. A. Evans
Other Remuneration - Pfizer
M. Schmidt
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
A. Makris
No relevant relationships to disclose
R. Grieve
No relevant relationships to disclose
S. Loibl
No relevant relationships to disclose
L. Maher
No relevant relationships to disclose
K. Mousa
No relevant relationships to disclose
K. Buchsenscuhtz
No relevant relationships to disclose
R. A'Hern
No relevant relationships to disclose
J. M. Bliss
Research Funding - Pfizer